AMRX Quote, Financials, Valuation and Earnings

Eyenovia has a net margin of -0.02% compared to Amneal Pharmaceuticals's net margin of -485406.34%. Amneal Pharmaceuticals's return on equity of -587.3% beat Eyenovia's return on equity of -676.86%.

Amneal Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 35.14%. On the other hand Eyenovia has an analysts' consensus of $3.50 which suggests that it could grow by 1563.89%. Given that Eyenovia has higher upside potential than Amneal Pharmaceuticals, analysts believe Eyenovia is more attractive than Amneal Pharmaceuticals.

Amneal Pharmaceuticals has a beta of 1.102, which suggesting that the stock is 10.226% more volatile than S&P 500. In comparison Eyenovia has a beta of 1.306, suggesting its more volatile than the S&P 500 by 30.593%.

Amneal Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eyenovia offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amneal Pharmaceuticals pays -- of its earnings as a dividend. Eyenovia pays out -- of its earnings as a dividend.

Amneal Pharmaceuticals quarterly revenues are $702.5M, which are larger than Eyenovia quarterly revenues of $1.6K. Amneal Pharmaceuticals's net income of -$156K is higher than Eyenovia's net income of -$7.9M. Notably, Amneal Pharmaceuticals's price-to-earnings ratio is 101.17x while Eyenovia's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amneal Pharmaceuticals is 0.86x versus 205.54x for Eyenovia. Usually stocks with elevated PS ratios are considered overvalued.

KORU Medical Systems has a net margin of -0.02% compared to Amneal Pharmaceuticals's net margin of -19.33%. Amneal Pharmaceuticals's return on equity of -587.3% beat KORU Medical Systems's return on equity of -57.92%.

Amneal Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 35.14%. On the other hand KORU Medical Systems has an analysts' consensus of $4.30 which suggests that it could grow by 22.5%. Given that Amneal Pharmaceuticals has higher upside potential than KORU Medical Systems, analysts believe Amneal Pharmaceuticals is more attractive than KORU Medical Systems.

Amneal Pharmaceuticals has a beta of 1.102, which suggesting that the stock is 10.226% more volatile than S&P 500. In comparison KORU Medical Systems has a beta of 0.446, suggesting its less volatile than the S&P 500 by 55.418%.

Amneal Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. KORU Medical Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amneal Pharmaceuticals pays -- of its earnings as a dividend. KORU Medical Systems pays out -- of its earnings as a dividend.

Amneal Pharmaceuticals quarterly revenues are $702.5M, which are larger than KORU Medical Systems quarterly revenues of $8.2M. Amneal Pharmaceuticals's net income of -$156K is higher than KORU Medical Systems's net income of -$1.6M. Notably, Amneal Pharmaceuticals's price-to-earnings ratio is 101.17x while KORU Medical Systems's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amneal Pharmaceuticals is 0.86x versus 5.72x for KORU Medical Systems. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -0.02% compared to Amneal Pharmaceuticals's net margin of -49.65%. Amneal Pharmaceuticals's return on equity of -587.3% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Amneal Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 35.14%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $7.30 which suggests that it could grow by 479.77%. Given that NovaBay Pharmaceuticals has higher upside potential than Amneal Pharmaceuticals, analysts believe NovaBay Pharmaceuticals is more attractive than Amneal Pharmaceuticals.

Amneal Pharmaceuticals has a beta of 1.102, which suggesting that the stock is 10.226% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.646, suggesting its less volatile than the S&P 500 by 35.372%.

Amneal Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amneal Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Amneal Pharmaceuticals quarterly revenues are $702.5M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Amneal Pharmaceuticals's net income of -$156K is higher than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Amneal Pharmaceuticals's price-to-earnings ratio is 101.17x while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amneal Pharmaceuticals is 0.86x versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -0.02% compared to Amneal Pharmaceuticals's net margin of -2357.27%. Amneal Pharmaceuticals's return on equity of -587.3% beat Palatin Technologies's return on equity of --.

Amneal Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 35.14%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1140.88%. Given that Palatin Technologies has higher upside potential than Amneal Pharmaceuticals, analysts believe Palatin Technologies is more attractive than Amneal Pharmaceuticals.

Amneal Pharmaceuticals has a beta of 1.102, which suggesting that the stock is 10.226% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.929%.

Amneal Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amneal Pharmaceuticals pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Amneal Pharmaceuticals quarterly revenues are $702.5M, which are larger than Palatin Technologies quarterly revenues of $350K. Amneal Pharmaceuticals's net income of -$156K is higher than Palatin Technologies's net income of -$7.8M. Notably, Amneal Pharmaceuticals's price-to-earnings ratio is 101.17x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amneal Pharmaceuticals is 0.86x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.